Sanctuary Advisors LLC Takes Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Sanctuary Advisors LLC acquired a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 23,672 shares of the medical research company’s stock, valued at approximately $5,422,000.

Several other institutional investors have also modified their holdings of the stock. Boston Trust Walden Corp increased its stake in Charles River Laboratories International by 2.8% during the 2nd quarter. Boston Trust Walden Corp now owns 200,314 shares of the medical research company’s stock worth $41,381,000 after buying an additional 5,375 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its holdings in Charles River Laboratories International by 5.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 56,840 shares of the medical research company’s stock valued at $15,401,000 after purchasing an additional 2,739 shares in the last quarter. Global Assets Advisory LLC acquired a new stake in Charles River Laboratories International during the 1st quarter worth $8,301,000. Natixis purchased a new stake in shares of Charles River Laboratories International during the first quarter worth $1,058,000. Finally, D. Scott Neal Inc. acquired a new stake in shares of Charles River Laboratories International in the first quarter valued at about $8,928,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Up 0.6 %

Charles River Laboratories International stock opened at $190.72 on Friday. The company has a market capitalization of $9.82 billion, a P/E ratio of 22.44, a PEG ratio of 4.09 and a beta of 1.36. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.21 and a current ratio of 1.58. Charles River Laboratories International, Inc. has a fifty-two week low of $161.65 and a fifty-two week high of $275.00. The stock has a 50-day simple moving average of $204.77 and a 200-day simple moving average of $219.88.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 7th. The medical research company reported $2.80 EPS for the quarter, beating analysts’ consensus estimates of $2.39 by $0.41. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.03 billion. Equities research analysts expect that Charles River Laboratories International, Inc. will post 10.01 earnings per share for the current year.

Charles River Laboratories International announced that its board has approved a stock repurchase plan on Wednesday, August 7th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase up to 9.6% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Argus reaffirmed a “hold” rating on shares of Charles River Laboratories International in a research note on Friday, June 28th. StockNews.com upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating in a research report on Tuesday, August 20th. UBS Group reduced their target price on Charles River Laboratories International from $290.00 to $240.00 and set a “buy” rating on the stock in a research report on Thursday, August 8th. Mizuho assumed coverage on Charles River Laboratories International in a research report on Friday, June 7th. They set a “neutral” rating and a $235.00 price objective for the company. Finally, The Goldman Sachs Group lowered their target price on shares of Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $220.25.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).